Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib + Erlotinib in EGFR-mutated NSCLC
NCT02206763Phase 1Terminated
- Sponsor
- GSK
- Start
- Oct 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of momelotinib dihydrochloride in non-small cell lung cancer (NSCLC), sponsored by GSK. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Incidence of Adverse Events at 2 years and 2 more. Started Oct 2014; status: terminated.
02
Drugs
momelotinib dihydrochloride
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02206763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02206763.